25.72USD-2.46%Mkt Cap: 304.31M USDP/E: —Last update: 2026-05-26
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target variou…
Industry Peers
BiotechnologyIndicators:|
Key Statistics
Company
Market Cap304.31M USD
Enterprise Value214.39M USD
Revenue (TTM)7.49M USD
Gross Profit-24.64M USD
Net Income (TTM)-242.03M USD
Revenue/Share0.8050 USD
Last Price25.72 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees44
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.80
PEG—
EV/EBITDA-5.02
EV/Revenue28.61
P/S41.97
P/B-1.41
EPS (TTM)-36.59
EPS (Forward)-3.98
52W Range
7.36866% of range35.00
52W High35.00 USD
52W Low7.368 USD
Profitability
Gross Margin0.00%
Oper. Margin-209.12%
EBITDA Margin0.00%
Profit Margin-6960.77%
ROE128.90%
ROA-245.15%
Growth
Revenue Growth408.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-30.24M USD
CapEx (TTM)128.00K USD
FCF Margin-348.37%
FCF Yield-8.58%
Net Debt-100.13M USD
Net Debt/EBITDA2.35
Balance Sheet
Debt/Equity-0.04
Current Ratio11.91
Quick Ratio11.70
Book Value/Sh-19.2090 USD
Cash/Share9.208 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateDec 14, 2023
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)42.50 USD
Target Range40.00 USD – 44.00 USD
# Analysts4
Ownership
Shares Out.11.61M
Float4.68M
Insiders3.18%
Institutions101.88%
Short Interest
Short Ratio4.3d
Short % Float9.03%
Short % Out.4.92%
Shares Short565.31K
Short (prev mo.)345.45K
Technical
SMA 5028.89 (-11.0%)
SMA 20020.10 (+28.0%)
Beta0.59
S&P 52W Chg28.31%
Avg Vol (30d)110.97K
Avg Vol (10d)78.27K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—